SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Piramal Pharma informs about newspaper advertisement

24 Aug 2023 Evaluate

Further to its letters dated February 8, 2023, March 28, 2023 and July 27, 2023, Piramal Pharma has informed that it enclosed copies of advertisement issued by the Company today, 24th August, 2023, in respect of matters specified under subregulation (1) of Regulation 92 of SEBI ICDR Regulations, in all editions of Financial Express (English national daily newspaper with wide circulation), Jansatta (Hindi national daily newspaper with wide circulation), and Navshakti (Marathi being the regional language in the place where its Registered and Corporate Office is located).

The above information is a part of company’s filings submitted to BSE.

Piramal Pharma Share Price

148.90 1.45 (0.98%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×